Suppression or induction of apoptosis by opposing pathways downstream from calcium-activated calcineurin

  1. Joseph Lotem,
  2. Rachel Kama, and
  3. Leo Sachs*
  1. Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 76100, Israel
  1. Contributed by Leo Sachs

Abstract

Ca2+-mobilizing compounds such as the Ca2+ ionophore A23187 or the endoplasmic reticulum Ca2+ ATPase inhibitor thapsigargin can suppress or induce apoptosis in the same cells. The use of different calcineurin inhibitors has shown that both suppression and induction of apoptosis by the Ca2+-mobilizing compounds were mediated by calcineurin activation. Ca2+-mobilizing compounds activated p38 and p44/42 mitogen-activated protein kinases (MAPKs). Induction of apoptosis by the Ca2+-mobilizing compounds was suppressed by an inhibitor of p38 MAPK but not by an inhibitor of p44/42 MAPK. These MAPK inhibitors did not suppress apoptosis induction by wild-type p53 or by withdrawal of IL-6 from IL-6-dependent cells that are mediated by calcineurin-independent pathways. These MAPK inhibitors also did not affect the ability of Ca2+-mobilizing compounds to suppress apoptosis. The results indicate that (i) Ca2+- mobilizing compounds activate different and opposing pathways that diverge downstream from calcineurin activation that can either suppress or induce apoptosis in the same cells; (ii) p38 MAPK but not p44/42 MAPK is involved in induction of apoptosis but not in its suppression by the Ca2+-mobilizing compounds; and (iii) neither p38 nor p44/42 MAPKs mediate induction of apoptosis by some calcineurin-independent pathways.

Footnotes

  • * To whom reprint requests should be addressed. E-mail: lgsachs{at}weizmann.weizmann.ac.il.

  • Abbreviations:
    CsA,
    cyclosporin A;
    FKBP,
    FK506 binding protein;
    MAPK,
    mitogen-activated protein kinase;
    PI3K,
    phosphatidylinositol 3-kinase;
    TG,
    thapsigargin
« Previous | Next Article »Table of Contents